louisiana glp-1 stomach paralysis lawsuit SURGE IN DRUGS LIKE OZEMPIC SPARKS THOUSANDS OF LAWSUITS OVER ALLEGED SIDE EFFECTS The medications, initially for type 2 diabetes, have driven widespread off-label weight-loss use amid reported gastrointestinal injuries and Makers of weight-loss, diabetes medication

The Intestinal Microenvironment and Functional Gastrointestinal Disorders

10.1161/HYPERTENSIONAHA.115.05779 47

Glucagon-like peptide-1 receptor in the human hypothalamus is associated with body mass index and colocalizes with the anorexigenic neuropeptide nucleobindin-2/nesfatin-1

Visiongain Insight: Competition in next-generation obesity therapies will increasingly depend on efficacy, preservation of lean mass, cardiovascular outcomes and dosing convenience

Our choice today is toasted coconut

Competitive Landscape: Market Leaders and Emerging Challengers The GLP-1 obesity market has crystallized into one of the most concentrated competitive dynamics in pharmaceutical history